company background image
N4CN logo

Paratek Pharmaceuticals DB:N4CN Stock Report

Last Price

€2.02

Market Cap

€120.0m

7D

0.4%

1Y

-13.9%

Updated

22 Sep, 2023

Data

Company Financials +

Paratek Pharmaceuticals, Inc.

DB:N4CN Stock Report

Market Cap: €120.0m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

N4CN Stock Overview

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.

N4CN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Paratek Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Paratek Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.02
52 Week HighUS$3.65
52 Week LowUS$1.19
Beta1.7
1 Month Change2.90%
3 Month Changen/a
1 Year Change-13.95%
3 Year Change-57.52%
5 Year Change-75.32%
Change since IPO-86.37%

Recent News & Updates

Recent updates

Shareholder Returns

N4CNDE PharmaceuticalsDE Market
7D0.4%-0.2%0.4%
1Y-13.9%-25.2%6.7%

Return vs Industry: N4CN underperformed the German Pharmaceuticals industry which returned -3.5% over the past year.

Return vs Market: N4CN underperformed the German Market which returned 14.4% over the past year.

Price Volatility

Is N4CN's price volatile compared to industry and market?
N4CN volatility
N4CN Average Weekly Movement5.7%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.7%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.5%

Stable Share Price: N4CN has not had significant price volatility in the past 3 months.

Volatility Over Time: N4CN's weekly volatility has decreased from 15% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996269Evan Lohhttps://www.paratekpharma.com

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.

Paratek Pharmaceuticals, Inc. Fundamentals Summary

How do Paratek Pharmaceuticals's earnings and revenue compare to its market cap?
N4CN fundamental statistics
Market cap€119.98m
Earnings (TTM)-€58.88m
Revenue (TTM)€166.13m

0.7x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
N4CN income statement (TTM)
RevenueUS$177.00m
Cost of RevenueUS$64.13m
Gross ProfitUS$112.87m
Other ExpensesUS$175.60m
Earnings-US$62.73m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.09
Gross Margin63.77%
Net Profit Margin-35.44%
Debt/Equity Ratio-128.3%

How did N4CN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.